Assetmark, Inc Design Therapeutics, Inc. Transaction History

Assetmark, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$2.05 - $8.14 $924 - $3,671	451 Added 24.07%	2,325 $5,000
Q2 2023 Aug 11, 2023	BUY	$4.99 - $7.64 $1,077 - $1,650	216 Added 13.03%	1,874 $11,000
Q1 2023 May 05, 2023	BUY	$5.5 - $9.77 $3,008 - $5,344	547 Added 49.23%	1,658 $9,000
Q4 2022 Feb 10, 2023	BUY	$7.86 - $17.2 $2,821 - $6,174	359 Added 47.74%	1,111 $11,000
Q3 2022 Nov 01, 2022	BUY	$14.09 - $25.57 $1,549 - $2,812	110 Added 17.13%	752 $13,000
Q2 2022 Aug 03, 2022	BUY	$9.91 - $17.33 $3,755 - $6,568	379 Added 144.11%	642 $9,000
Q1 2022 May 13, 2022	BUY	$11.17 - $20.89 $2,937 - $5,494	263 New	263 $4,000

102

31M

2.3K

16.5K

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $347M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.